Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors;Indikationen zur prä- und postoperativen therapie mit imatinib bei gastrointestinalen stromatumoren

Chirurg

Volumn 79, Issue 7, 2008, Pages 630-637

  Heger, U ^a   Weitz, J ^a   Lordick, F ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Adjuvant; Gastrointestinal stromal tumors; Imatinib; KIT receptor; Neoadjuvant

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; DISEASE COURSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROGNOSIS; PYRIMIDINES; SURVIVAL RATE;

EID: 46649101591     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-008-1526-6     Document Type: Article

References (37)

1. Antonescu CR, Besmer P, Guo T et al. (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182-4190
2. Benjamin RS, Choi H, Macapinlac HA et al. (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25: 1760-1764
3. Blanke C, Rankin C, Demetri RG et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26: 626-632
4. Blay JY, Le Cesne A, Ray-Coquard I et al. (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25: 1107-1113
5. Choi H, Charnsangavej C, Faria SC et al. (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25: 1753-1759
6. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813-3825
7. Debiec-Rychter M, Dumez H, Judson I et al. (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 40: 689-695
8. DeMatteo RP, Antonescu CR, Chadaram V et al. (2005) Adjuvant imatinib mesylate in pazients with primary high risk gastrointestinal sromal tumors (GIST) following complete resection: safety results from the U.S. Intergroup phase II trial ACOSOG Z9000. J Clin Oncol 23 [Suppl 1]: 9009 (abstr)
9. DeMatteo RP, Gold JS, Saran L et al. (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) Cancer 112: 608-615
10. DeMatteo RP, Lewis JJ, Leung D et al. (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival 231: 51-58
11. DeMatteo RP, Maki RG, Singer S et al. (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor 245: 347-52
12. DeMatteo RP, Owzar K, Antonescu CR et al. (2008) Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. 2008 Gastrointestinal Cancers Symposoium, abstr 8
13. DeMatteo RP, Owzar K, Maki R et al. (2007) Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. J Clin Oncol 25 [Suppl 18]: 10079 (abstr)
14. Demetri GD, Benjamin RS, Blanke CD et al. (2007) NCCN Task force report: optimal management of patients with Gastrointestinal Stromal Tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5 [Suppl 2]: 1-29
15. Demetri GD, von Mehren M, Blanke CD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480
16. Emory TS, Sobin LH, Lukes L et al. (1999) Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site 23: 82-87
17. Fletcher CD, Berman JJ, Corless C et al. (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33: 459-465
18. Hassan I, You YN, Shyyan R et al. (2008) Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis 15: 52-59
19. Heinrich MC, Corless CL, Blanke CD et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 4764-4774
20. Heinrich MC, Corless CL, Demetri GD et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349
21. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580
22. Katz SC, DeMatteo RP (2008) Gastrointestinal stromal tumors and leiomyosarcomas 97: 350-359
23. Kindblom LG, Remotti HE, Aldenborg F et al. (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of cajal 152: 1259-1269
24. Loughrey MB, Mitchell C, Mann GB et al. (2005) Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol 58: 779-781
25. Maki RG, Fletcher JA, Heinrich CM et al. (2005) Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol ASCO Ann Meet Proc Vol 23, 16S, Part I: 9011 (abstr)
26. Miettinen M, Lasota J (2003) Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 54: 3-24
27. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70-83
28. Savage DG, Antman KH (2002) Imatinib mesylate-a new oral targeted therapy. N Engl J Med 346: 683-693
29. Stroobants S, Goeminne J, Seegers M et al. (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39: 2012-2020
30. Tornillo L, Terracciano LM (2005) An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 59: 557-563
31. Tran T, Davila JA, El-Serag HB (2005) The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000 100: 162-168
32. Van Glabbeke M, Verweij J, Casali PG et al. (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a european organisation for research and treatment of cancer-italian sarcoma group-australasian gastrointestinal. Trials Group study 23: 5795-5804
33. Van Glabbeke MM, Owzar K, Rankin C et al. (2007) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts). J Clin Oncol 25 [Suppl 18]: 10004 (abstr)
34. van Oosterom AT, Judson I, Verweij J et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421-1423
35. Verweij J, Casali PG, Zalcberg J et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127-1134
36. Verweij J, van Oosterom A, Blay JY et al. (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC soft tissue and bone sarcoma group phase II study. Eur J Cancer 39: 2006-2011
37. Wardelmann E, Merkelbach-Bruse S, Pauls K et al. (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12: 1743-1749